58 Results

People

  1. Mato
    Mato
  2. Roeker
    Roeker
  3. Lamanna
    Lamanna
  4. Tallman
    Tallman
  5. Dogan
    Dogan
  6. Landgren
    Landgren
  7. Zelenetz
    Zelenetz
  8. Brentjens
    Brentjens
  9. Joseph
    Joseph
  10. Offit
    Offit

Groups

  1. Department of Medicine (43)
  2. Hematologic Malignancies, Division of (38)
  3. Center for Hematologic Malignancies (33)
  4. Adult Leukemia (23)
  5. GSK Faculty (6)
  6. Lymphoma (6)
  7. Department of Pathology and Laboratory Medicine (5)
  8. Hematologic Malignancies Research (5)
  9. Solid Tumor Oncology Division (5)
  10. Biostatistics Service (4)
  1. "chronic lymphocytic leukemia"
Formats
  1. Journal Article (46)
  2. Meeting Abstract (5)
  3. Review (5)
  4. Research Letter (2)
Groups
  1. Department of Medicine (43)
  2. Hematologic Malignancies, Division of (38)
  3. Center for Hematologic Malignancies (33)
  4. Adult Leukemia (23)
  5. GSK Faculty (6)
  6. Lymphoma (6)

More Groups

People
  1. Anthony Mato (15)
  2. Lindsey Roeker (8)
  3. Martin Tallman (5)
  4. Nicole Lamanna (4)
  5. Ahmet Dogan (3)
  6. Andrew Zelenetz (3)

More People

Years
  1. 2025 (4)
  2. 2024 (1)
  3. 2023 (3)
  4. 2022 (4)
  5. 2021 (5)
  6. 2020 (6)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (5)
  2. Leukemia and Lymphoma (5)
  3. Leukemia Research (4)
  4. Current Hematologic Malignancy Reports (3)
  5. American Journal of Hematology (2)
  6. Cancer Biology and Therapy (2)

More Publications

Publishers
  1. Elsevier Inc. (11)
  2. Taylor & Francis Group (7)
  3. Springer (5)
  4. Elsevier Ltd (4)
  5. John Wiley & Sons (3)
  6. Wiley Blackwell (3)

More Publishers

Results (58)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world effectiveness of frontline treatments among patients with chronic lymphocytic leukemia: Results from ConcertAI
    Journal Article

    Roeker, L. E.; Burke, J. M.; Rhodes, J. M.; Emechebe, N.; Jawaid, D.; Manzoor, B. S.; Jensen, C. E.; Ryland, L.; Liu, Y.; Marx, S. E.; more...
    Cancers (2025)

    Fulltext@MSK | Save
  • BTK inhibitors versus venetoclax as first- or second-line therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world evidence study
    Research Letter

    Roeker, L. E.; Han, Y.; Teschemaker, A.; Mato, A. R.; Thompson, M. C.
    American Journal of Hematology (2025)

    Fulltext@MSK | Save
  • Treatment effectiveness of venetoclax-based therapy after Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: An International Real-World Study
    Research Letter

    Ghosh, N.; Eyre, T. A.; Brown, J. R.; Lamanna, N.; Manzoor, B. S.; Coombs, C. C.; Tuncer, H. H.; Ujjani, C.; Leslie, L. A.; Roeker, L. E.; more...
    American Journal of Hematology (2025)

    Fulltext@MSK | Save
  • Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
    Journal Article

    Shadman, M.; Salkar, M.; Srivastava, B.; Karve, S.; Emond, B.; Gogna, P.; Manceur, A. M.; Lafeuille, M. H.; Rava, A.; Sun, H.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed/refractory CLL/SLL: Results from BTK-naïve cohort in the phase 1/2 BRUIN study
    Meeting Abstract

    Wierda, W. G.; Eyre, T. A.; Lech-Maranda, E.; Roeker, L. E.; Patel, M.; Fukuhara, N.; Woyach, J. A.; Brown, J. R.; Patel, K.; Tam, C. S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: A real-world database study
    Journal Article

    Eyre, T. A.; Hess, L. M.; Sugihara, T.; He, D.; Khanal, M.; Pagel, J. M.; Walgren, R. A.; Abada, P. B.; Konig, H.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP workshop
    Review

    Czader, M.; Amador, C.; Cook, J. R.; Thakkar, D.; Parker, C.; Dave, S. S.; Dogan, A.; Duffield, A. S.; Nejati, R.; Ott, G.; more...
    American Journal of Clinical Pathology (2023)

    Fulltext@MSK | Save
  • Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: Identifying risk factors to help guide treatment selection
    Journal Article

    Bantilan, K. S.; Kay, N. E.; Parikh, S. A.; Rabe, K. G.; Call, T. G.; Leis, J. F.; Ding, W.; Slager, S. L.; Soumerai, J. D.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • BRUIN CLL-322: A phase 3 open-label, randomized study of fixed-duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (Trial in progress)
    Meeting Abstract

    Wierda, W. G.; Pagel, J. M.; Davids, M. S.; Zinzani, P. L.; Lu, Y.; Liu, H.; Shahda, S.; Leow, C. C.; Tam, C. S.; Woyach, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor-pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (Trial in progress)
    Meeting Abstract

    Hill, M.; Sharman, J. P.; Jurczak, W.; Coombs, C. C.; Wang, D.; Ku, N. C.; Guntur, A.; Shahda, S.; Leow, C. C.; Ghia, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save